NCT05620134 - Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

October 17, 2025

Study Completion Date

February 20, 2026

Conditions

CancerTumor, SolidAdvanced Solid TumorMetastatic CancerMelanomaColorectal CancerNon-small Cell Lung CancerSmall-cell Lung CancerUrothelial CarcinomaSquamous Cell Carcinoma of Head and NeckLuminal Breast CancerTriple Negative Breast CancerClear Cell Renal Cell CarcinomaPapillary Renal Cell CarcinomaGastric AdenocarcinomaGastroEsophageal CancerSquamous Cell Carcinoma SkinPancreatic AdenocarcinomaHepatocellular CarcinomaColorectal AdenocarcinomaEpithelial Ovarian CancerThyroid Cancer

Interventions

DRUG

JK08

Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.

DRUG

Pembrolizumab

Immune checkpoint inhibitor

DRUG

Lenvatinib Pill

Multi-kinase inhibitor

Trial Locations (11)

1070

Institut Jules Bordet, Brussels

9000

UZ Ghent, Ghent

Unknown

UZA, Edegem

CHU UCL Namur - site Godinne, Yvoir

NEXT Oncology Barcelona, Barcelona

Vall d Hebron Institute of Oncology VHIO, Barcelona

Next Oncology Madrid Hospital Quironsalud Madrid, Madrid

NEXT Oncology Madrid, Madrid

START Madrid, Madrid

University Hospital October 12, Madrid

Instituto de Investigación Sanitaria INCLIVA, Valencia

All Listed Sponsors

lead

Salubris Biotherapeutics Inc

INDUSTRY